Stability indicating RP-HPLC method development and validation for simultaneous estimation of metformin hydrochloride and remogliflozin etabonate in bulk and tablet formulation

A simple efficient stability-indicating validated RP-HPLC method has been developed for the simultaneous determination of Metformin hydrochloride (MET) and Remogliflozin etabonate (REM) in bulk and was applied to marketed formulations. The mobile phase used for detection was Phosphate Buffer (pH 4.0): Acetonitrile (60:40%v/v). Drug peaks were detected by a UV detector at 226nm. The linearity of the developed method was found to be 20-60μg/mL for Metformin hydrochloride and 4-12μg/mL for Remogliflozin etabonate. The Limit of Detection (LOD.) and Limit of Quantitation (LOQ.) were found to be 0.085μg/mL and 0.258μg/mL for MET and 0.010μg/mL and 0.030μg/mL for REM respectively. Hydrolysis by HCl, NaOH, hydrogen peroxide, UV light and temperature were performed on a formulation which proves that the proposed method was specific and will be suitable for routine quality control analysis.